STRO Sutro Biopharma, Inc. - Common Stock
$22,94
السعر · أغسطس 19, 2026
البيانات الأساسية اعتبارًا من أغسطس 12, 2026
نطاق 52 أسبوعًا
$1–$44
51% of range
تقييم المحللين
BUY
19 analysts
السعر المستهدف
$48
+108% upside
P/E (TTM)
-1.0
ROE
232.2%
هامش صافي الربح
-186.5%
حول Sutro Biopharma, Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
اقرأ المزيد
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically validated targets for which the current standard of care is suboptimal.
Technology
Sutro's Xpress CF Platform is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.
Collaborations
In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014. In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.
== References ==
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
STRO لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$22.94
القيمة السوقية
$197M
P/E (TTM)
-1.0
ربح السهم (آخر 12 شهرًا)
$-22.49
الإيرادات (آخر 12 شهرًا)
$102M
عائد التوزيعات
—
ROE
232.2%
D/E الدين/حقوق الملكية
—
نطاق 52 أسبوعًا
$1 – $44
STRO مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$102M
2016-12-31
→
2025-12-31
ربح السهم
$-22.49
2020-12-31
→
2025-12-31
التدفق النقدي الحر
—
2018-12-31
→
2018-12-31
الهوامش
-186.5%
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
STRO
متوسط الأقران
P/E (TTM)
-1.0
6.1
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
1.9
7.7
P/B (السعر / القيمة الدفترية)
-1.5
2.2
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
STRO
متوسط الأقران
Operating Margin (هامش التشغيل)
-154.5%
—
Net Profit Margin (هامش صافي الربح)
-186.5%
-60.9%
ROA (العائد على الأصول)
-68.1%
-50.0%
ROE
232.2%
-44.8%
ROIC
119.5%
—
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
STRO
متوسط الأقران
Current Ratio (النسبة الحالية)
2.0
5.9
Quick Ratio (النسبة السريعة)
1.9
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
STRO
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
65.2%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
14.8%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
19.1%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
STRO
متوسط الأقران
STRO توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
19 محللين
- شراء قوي 5 26,3%
- شراء 12 63,2%
- احتفاظ 1 5,3%
- بيع 1 5,3%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
13 محللين · 2026-08-13
الوسيط
$50.00
الآن
$22.94
منخفض
$10.00
مرتفع
$61.00
السعر المستهدف الوسيط
$50.00
+118,0%
السعر المستهدف المتوسط
$47.77
+108,2%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
-0.34%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 31 مارس، 2026 | $-2.94 | $-3.85 | 0.91% |
| 31 ديسمبر، 2025 | $-5.29 | $-4.43 | -0.86% |
| 30 سبتمبر، 2025 | $-6.70 | $-4.23 | -2.5% |
| 30 يونيو، 2025 | $-1.40 | $-4.10 | 2.7% |
| 31 مارس، 2025 | $-9.10 | $-7.22 | -1.9% |
| 31 ديسمبر، 2024 | $-8.90 | $-8.48 | -0.42% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | — |
| PALI | $375M | -7.8 | — | — | -25.4% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
| DMAC | $428M | — | — | — | -78.7% | — |
| ABEO | $290M | 5.2 | 147.5% | 1223.1% | 44.1% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
| SABS | — | — | — | — | — | — |
| TLSI | — | — | — | — | — | — |
| IMRX | — | -5.2 | — | — | -45.3% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 15
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
الميزانية العمومية 24
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
التدفق النقدي 16
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
الربحية 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
السيولة والملاءة 5
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
الكفاءة 2
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
معدلات النمو 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 14
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
قائمة الدخل 13
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $9M | $25M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $43M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $58M | $46M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-49M | $-21M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-35M | $-19M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $0 | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-35M | $-19M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | · | $-21M |
الميزانية العمومية 23
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $47M | $97M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | · | $191M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | · | $11M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | · | $11M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | · | $347M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | · | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | · | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | · | $12M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | · | $10M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | · | $58M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | · | $31M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | · | $133.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | · | $171M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | · | $55.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | · | $-418M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | · | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $217M | $230M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | · | 54,631,360 |
التدفق النقدي 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $6M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $-24M | $66M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-38M | $-78M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $12M | $30M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $-50M | $18M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
الربحية 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | · | -84.3% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | · | -77.5% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | · | -77.5% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | · | -84.3% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | · | -5.1% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | · | -7.6% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | · |
السيولة والملاءة 4
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | · | 5.9 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | · | 5.1 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 |
الكفاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | · | 2.1 |
التقييم (آخر 12 شهرًا) 12
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $105M | · | $99M | $115M | $65M | · | $64M | $66M | $53M | · | $65M | $76M | $72M | · | $68M | |
| Net Income TTM | $-145M | $-183M | · | $-193M | $-184M | $-231M | · | $-204M | $-194M | $-196M | · | $-157M | $-134M | $-135M | · | $-116M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | · | $303M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | |
| P/E | -4.6 | -1.9 | · | -0.4 | -0.3 | -0.2 | · | -1.3 | -1.1 | -2.0 | · | -1.3 | -1.9 | -1.8 | · | -2.3 | |
| P/S | 5.6 | 3.9 | · | 0.7 | 0.5 | 0.8 | · | 4.4 | 3.6 | 6.7 | · | 3.2 | 3.7 | 3.9 | · | 4.5 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -1.1 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | |
| Earnings Yield | -22.0% | -51.5% | · | -265.5% | -314.1% | -412.3% | · | -74.6% | -89.8% | -51.1% | · | -77.0% | -51.8% | -56.5% | · | -43.8% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $102M | $62M | $154M | $68M | $62M |
| هامش الربح التشغيلي % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| صافي الدخل | $-191M | $-227M | $-107M | $-119M | $-106M |
| EPS المخفف | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | — | — | 0.0 | 0.1 | 0.1 |
| النسبة الحالية | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| النسبة السريعة | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 111 مقدمي إقرار · $467.3M إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 46 (+21 مقابل الربع السابق) | 16 (+8 مقابل الربع السابق) | 20 (0 مقابل الربع السابق) | 19 (+5 مقابل الربع السابق) | +1.3M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43320887 | 1304846 | 9,27% | الأسهم |
| BVF INC/IL | $41559362 | 1251788 | 8,89% | الأسهم |
| Affinity Asset Advisors, LLC | $38926568 | 1172487 | 8,33% | الأسهم |
| SAMSARA BIOCAPITAL, LLC | $35287350 | 1062872 | 7,55% | الأسهم |
| Kynam Capital Management, LP | $28968926 | 872558 | 6,20% | الأسهم |
| ORBIMED ADVISORS LLC | $24698941 | 743944 | 5,29% | الأسهم |
| Balyasny Asset Management L.P. | $23610578 | 711162 | 5,05% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $23048071 | 694219 | 4,93% | الأسهم |
| EVENTIDE ASSET MANAGEMENT, LLC | $19430698 | 585262 | 4,16% | الأسهم |
| Velan Capital Investment Management LP | $17003712 | 512160 | 3,64% | الأسهم |
| Woodline Partners LP | $15206563 | 458029 | 3,25% | الأسهم |
| ADAR1 Capital Management, LLC | $13413265 | 404014 | 2,87% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $12150270 | 365972 | 2,60% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $11027500 | 332057 | 2,36% | الأسهم |
| STATE STREET CORP | $10158503 | 305979 | 2,17% | الأسهم |
| Merck & Co., Inc. | $9042053 | 272351 | 1,93% | الأسهم |
| ACUTA CAPITAL PARTNERS, LLC | $8972333 | 270251 | 1,92% | الأسهم |
| AMERIPRISE FINANCIAL INC | $8123011 | 244669 | 1,74% | الأسهم |
| Point72 Asset Management, L.P. | $7895856 | 237827 | 1,69% | الأسهم |
| KVP Capital Advisors, LP | $7522290 | 226575 | 1,61% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $6696042 | 201688 | 1,43% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6559058 | 197562 | 1,40% | الأسهم |
| UBS Group AG | $5407251 | 162869 | 1,16% | الأسهم |
| Seven Fleet Capital Management LP | $3794182 | 159118 | 0,81% | الأسهم |
| Qube Research & Technologies Ltd | $3539452 | 106610 | 0,76% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $3460502 | 104232 | 0,74% | الأسهم |
| CITADEL ADVISORS LLC | $3385205 | 101964 | 0,72% | الأسهم |
| MACKENZIE FINANCIAL CORP | $3146264 | 94767 | 0,67% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $2865957 | 86324 | 0,61% | الأسهم |
| MARSHALL WACE, LLP | $2448865 | 73761 | 0,52% | الأسهم |
| Y-Intercept (Hong Kong) Ltd | $1855183 | 55879 | 0,40% | الأسهم |
| Squarepoint Ops LLC | $1843895 | 55539 | 0,39% | الأسهم |
| XTX Topco Ltd | $1732011 | 52169 | 0,37% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1636826 | 49302 | 0,35% | الأسهم |
| Sigma Planning Corp | $1494664 | 45020 | 0,32% | الأسهم |
| Fisher Asset Management, LLC | $1171794 | 35295 | 0,25% | الأسهم |
| Elmind Capital, LP | $1063628 | 32037 | 0,23% | الأسهم |
| D. E. Shaw & Co., Inc. | $1000250 | 30128 | 0,21% | الأسهم |
| GOLDMAN SACHS GROUP INC | $975814 | 29392 | 0,21% | الأسهم |
| Trexquant Investment LP | $917515 | 27636 | 0,20% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $909116 | 27383 | 0,19% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $863897 | 26021 | 0,18% | الأسهم |
| RHUMBLINE ADVISERS | $684845 | 20628 | 0,15% | الأسهم |
| JPMORGAN CHASE & CO | $625079 | 18743 | 0,13% | الأسهم |
| BlackRock, Inc. | $595276 | 17930 | 0,13% | الأسهم |
| SEI INVESTMENTS CO | $544048 | 16387 | 0,12% | الأسهم |
| Informed Momentum Co LLC | $538902 | 16232 | 0,12% | الأسهم |
| DEUTSCHE BANK AG\ | $516692 | 15563 | 0,11% | الأسهم |
| RBF Capital, LLC | $507030 | 15272 | 0,11% | الأسهم |
| WELLS FARGO & COMPANY/MN | $449661 | 13544 | 0,10% | الأسهم |
| AJU IB Investment Co., Ltd. | $435925 | 17500 | 0,09% | الأسهم |
| Bank of New York Mellon Corp | $434522 | 13088 | 0,09% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $368520 | 11100 | 0,08% | عقد خيار الشراء |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $365200 | 11000 | 0,08% | عقد خيار البيع |
| MetLife Investment Management, LLC | $312113 | 9401 | 0,07% | الأسهم |
| Walleye Capital LLC | $308959 | 9306 | 0,07% | الأسهم |
| Integrated Quantitative Investments LLC | $296775 | 8939 | 0,06% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $279743 | 8426 | 0,06% | الأسهم |
| Lighthouse Investment Partners, LLC | $277818 | 8368 | 0,06% | الأسهم |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $242792 | 7313 | 0,05% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $242360 | 7300 | 0,05% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $232433 | 7001 | 0,05% | الأسهم |
| Persistent Asset Partners Ltd | $218091 | 6569 | 0,05% | الأسهم |
| CITIGROUP INC | $216995 | 6536 | 0,05% | الأسهم |
| Verdad Advisers, LP | $212480 | 6400 | 0,05% | الأسهم |
| Invesco Ltd. | $211119 | 6359 | 0,05% | الأسهم |
| HSBC HOLDINGS PLC | $205722 | 6234 | 0,04% | الأسهم |
| TWO SIGMA ADVISERS, LP | $203401 | 17580 | 0,04% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $185920 | 5600 | 0,04% | الأسهم |
| MORGAN STANLEY | $181870 | 5478 | 0,04% | الأسهم |
| Vanguard Global Advisers, LLC | $180774 | 5445 | 0,04% | الأسهم |
| Police & Firemen's Retirement System of New Jersey | $156173 | 4704 | 0,03% | الأسهم |
| Nuveen, LLC | $131837 | 3971 | 0,03% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $119520 | 3600 | 0,03% | الأسهم |
| Nuveen Asset Management, LLC | $103678 | 56347 | 0,02% | الأسهم |
| BARCLAYS PLC | $84228 | 2537 | 0,02% | الأسهم |
| NORTHERN TRUST CORP | $83100 | 2503 | 0,02% | الأسهم |
| State of Wyoming | $53718 | 1618 | 0,01% | الأسهم |
| Legal & General Group Plc | $51394 | 1548 | 0,01% | الأسهم |
| Ameritas Investment Partners, Inc. | $48074 | 1448 | 0,01% | الأسهم |
| FMR LLC | $44388 | 1337 | 0,01% | الأسهم |
| Russell Investments Group, Ltd. | $42330 | 1275 | 0,01% | الأسهم |
| VANGUARD GROUP INC | $36307 | 3138 | 0,01% | الأسهم |
| Tower Research Capital LLC (TRC) | $28751 | 866 | 0,01% | الأسهم |
| Point72 Asia (Singapore) Pte. Ltd. | $26943 | 31026 | 0,01% | الأسهم |
| CWM, LLC | $24487 | 983 | 0,01% | الأسهم |
| ROYAL BANK OF CANADA | $23000 | 687 | 0,00% | الأسهم |
| Owl Creek Wealth Partners LLC | $16302 | 491 | 0,00% | الأسهم |
| ACADIAN ASSET MANAGEMENT LLC | $12405 | 373839 | 0,00% | الأسهم |
| Sterling Capital Management LLC | $9329 | 281 | 0,00% | الأسهم |
| Quantbot Technologies LP | $6673 | 201 | 0,00% | الأسهم |
| Physician Wealth Advisors, Inc. | $6043 | 182 | 0,00% | الأسهم |
| MERCER GLOBAL ADVISORS INC /ADV | $3718 | 112 | 0,00% | الأسهم |
| OSAIC HOLDINGS, INC. | $3320 | 100 | 0,00% | الأسهم |
| PNC Financial Services Group, Inc. | $2058 | 62 | 0,00% | الأسهم |
| Fortitude Family Office, LLC | $1859 | 56 | 0,00% | الأسهم |
| Bogart Wealth, LLC | $1660 | 50 | 0,00% | الأسهم |
| Parallel Advisors, LLC | $1560 | 47 | 0,00% | الأسهم |
| NISA INVESTMENT ADVISORS, LLC | $1461 | 44 | 0,00% | الأسهم |
| Accredited Wealth Management, LLC | $869 | 5 | 0,00% | الأسهم |
المطلعون على الشركة 27 من المطلعين · مسؤولون 14 · مديرون 14
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| William J Newell | CEO | 3 مارس، 2023 M | 164816 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | 2 يونيو، 2026 M | 4725 | 0 | 0 | $0 |
| Edward C Albini | CFO and Secretary | 3 مارس، 2023 M | 87693 | 0 | 0 | $0 |
| Jane Chung | President and COO | 1 ديسمبر، 2023 A | 31698 | 0 | 0 | $0 |
| Hans-Peter Gerber | Chief Scientific Officer | 18 سبتمبر، 2023 A | — | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | 28 أغسطس، 2023 S | 0 | 0 | 0 | $0 |
| Nicki Vasquez | Chief Port. Strat & Alnce Ofcr | 12 يوليو، 2023 M | 24988 | 0 | 0 | $0 |
| Venkatesh Srinivasan | Chief Tech Op Officer | 1 مايو، 2023 A | — | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | 14 إبريل، 2023 M | 100368 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | Chief Medical Officer | 15 مارس، 2023 A | — | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | 3 مارس، 2023 M | 40827 | 0 | 0 | $0 |
| Linda A Fitzpatrick | Chief People & Comm. Officer | 3 مارس، 2023 M | 52690 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | 5 مارس، 2022 M | 37736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | 29 يناير، 2019 A | — | 0 | 0 | $0 |
| Heidi Hunter | مدير | 5 يونيو، 2026 A | — | 0 | 0 | $0 |
| Michael Dybbs | مدير | 5 يونيو، 2026 A | — | 0 | 0 | $0 |
| Jon Marc Wigginton | مدير | 5 يونيو، 2026 A | — | 0 | 0 | $0 |
| Sukhi Jagpal | مدير | 5 يونيو، 2026 A | — | 0 | 0 | $0 |
| Joseph M Lobacki | مدير | 5 يونيو، 2026 A | — | 0 | 0 | $0 |
| Daniel H Petree | مدير | 5 يونيو، 2026 A | 18601 | 0 | 0 | $0 |
| Connie Matsui | مدير | 5 يونيو، 2026 A | 50000 | 1 | 0 | $40000 |
| James P Panek | مدير | 5 يونيو، 2026 A | — | 0 | 0 | $0 |
| John Gordon Freund | مدير | 8 يونيو، 2023 A | 56327 | 0 | 0 | $0 |
| Shalini Sharp | مدير | 6 يونيو، 2022 A | — | 0 | 0 | $0 |
| Daniel Janney | مدير | 17 يونيو، 2019 A | 1944901 | 0 | 0 | $0 |
| Michael Jay Ross | مدير | 1 أكتوبر، 2018 C | 18248 | 0 | 0 | $0 |
| Bryan V Lawlis | مدير | 26 سبتمبر، 2018 A | — | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 1 حيازة
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | 9 أكتوبر، 2018 | — | إيداع أولي | استثمار سلبي | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 15 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 3826 SH | 8 أغسطس، 2026 | يومي |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,25% | 28745 SH | 8 أغسطس، 2026 | يومي |
| IWC · iShares Trust | 0,09% | 54216 SH | 8 أغسطس، 2026 | يومي |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 11715 SH | 8 أغسطس، 2026 | يومي |
| IWN · iShares Trust | 0,02% | 121308 SH | 8 أغسطس، 2026 | يومي |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 91894 SH | 8 أغسطس، 2026 | يومي |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 16520 SH | 8 أغسطس، 2026 | يومي |
| IWM · iShares Trust | 0,01% | 398610 SH | 8 أغسطس، 2026 | يومي |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 177152 SH | 8 أغسطس، 2026 | يومي |
| VHT · VANGUARD WORLD FUND | 0,01% | 47358 SH | 8 أغسطس، 2026 | يومي |
| IWO · iShares Trust | 0,00% | 22665 SH | 8 أغسطس، 2026 | يومي |
| ITOT · iShares Trust | 0,00% | 29451 SH | 8 أغسطس، 2026 | يومي |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 501524 SH | 8 أغسطس، 2026 | يومي |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2670 SH | 8 أغسطس، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1330 SH | 8 أغسطس، 2026 | يومي |